Related Experiment Video
Updated: Nov 30, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma
Thao Q Pham1, Kristin Robinson1, Lin Xu2,3
1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Abstract:
Rhabdomyosarcoma (RMS) is a devastating pediatric sarcoma. The survival outcomes remain poor for patients with relapsed or metastatic disease. Effective targeted therapy is lacking due to our limited knowledge of the underlying cellular and molecular mechanisms leading to disease progression. In this study, we used functional assays in vitro and in vivo (zebrafish and xenograft mouse models) to demonstrate the crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-renewal, and migration/invasion. Treatment with HDAC6-selective inhibitors recapitulates the HDAC6 loss-of-function phenotypes. HDAC6 regulates cytoskeletal dynamics to promote tumor cell migration and invasion. RAC1, a Rho family GTPase, is an essential mediator of HDAC6 function, and is necessary and sufficient for RMS cell migration and invasion. High expression of RAC1 correlates with poor clinical prognosis in RMS patients. Targeting the HDAC6-RAC1 axis represents a promising therapeutic option for improving survival outcomes of RMS patients.
Insights
Histone deacetylase 6 (HDAC6) drives pediatric rhabdomyosarcoma growth and spread. Targeting the HDAC6-RAC1 pathway offers a promising new therapy for this aggressive childhood cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pediatric Cancer Research
Background:
- Rhabdomyosarcoma (RMS) is a severe pediatric cancer with poor outcomes for relapsed or metastatic cases.
- Limited understanding of RMS progression hinders the development of effective targeted therapies.
Purpose of the Study:
- To investigate the role of histone deacetylase 6 (HDAC6) in RMS progression.
- To identify molecular targets for novel RMS therapies.
Main Methods:
- In vitro and in vivo functional assays (zebrafish and xenograft mouse models).
- Assessment of HDAC6-selective inhibitors.
- Analysis of RAC1 GTPase function and expression.
- Correlation of RAC1 expression with clinical prognosis.
Main Results:
- HDAC6 is crucial for RMS tumor growth, self-renewal, migration, and invasion.
- HDAC6 inhibition phenocopies loss-of-function effects.
- HDAC6 regulates cytoskeletal dynamics, promoting RMS cell migration.
- RAC1 is essential for HDAC6-mediated RMS cell migration and invasion.
- High RAC1 expression correlates with poor clinical prognosis in RMS patients.
Conclusions:
- The HDAC6-RAC1 axis is a key driver of RMS progression.
- Targeting this axis presents a promising therapeutic strategy for improving RMS patient survival.
Related Concept Videos
Abnormal Proliferation
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Hedgehog Signaling Pathway
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

